Cediranib |
AZD2171; AZD-2171; NSC-732208 |
Phase 2 Clinical |
Astrazeneca Plc |
Glioblastoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Biliary Tract Neoplasms; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Leukemia; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms |
Details
|
Kanitinib |
CX-1003 |
Phase 1 Clinical |
Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd |
Solid tumours; Esophageal Neoplasms; Prostatic Neoplasms |
Details
|
VEGFR-1/2 peptide vaccine (Keio University) |
|
Phase 2 Clinical |
Keio University |
Neurofibromatoses; Brain Neoplasms; Glioma |
Details
|
Glesatinib |
MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly |
Phase 2 Clinical |
Mirati Therapeutics |
Carcinoma, Non-Small-Cell Lung |
Details
|
Lucitanib |
AL-3810; CO-3810; S-80881 |
Phase 3 Clinical |
Advenchen Laboratories Nanjing Ltd |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
Metatinib Trometamol |
BMS-817378; SIM-817378 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Liver Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Olinvacimab |
SSS-23; TTAC-0001 |
Phase 2 Clinical |
Pharmabcine |
Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis |
Details
|
PZ-1 |
PZ-1 |
Phase 1 Clinical |
Chongqing University Of Arts And Sciences |
Solid tumours |
Details
|
SOMCL-15-290 |
SOMCL-15-290 |
Phase 1 Clinical |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Squamous Cell |
Details
|
PAN-90806 |
CP-632; OSI-632; CP-547632; PAN-90806 |
Phase 2 Clinical |
Pfizer Inc, Osi Pharmaceutical |
Ovarian Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration; Diabetic Retinopathy |
Details
|
LMV-12(HE003) |
LMV-12(HE003) |
Phase 1 Clinical |
Nanchang Hongyi Technology Co Ltd |
Solid tumours |
Details
|
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) |
|
Phase 2 Clinical |
Changchun Genescience Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
VEGFR2 peptide vaccine (VAXIMM) |
VXM-01 |
Phase 2 Clinical |
Merck Serono |
Pancreatic Neoplasms; Glioblastoma; Colorectal Neoplasms |
Details
|
CEP-11981 |
ESK-981; CEP-11981; SSR-106462; BOL-303213X |
Phase 2 Clinical |
Sanofi |
Prostatic Neoplasms |
Details
|
Ramucirumab biosimilar (CTTQ) |
|
Phase 1 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) |
BC-001 |
Phase 1 Clinical |
Shandong Buchang Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
Altiratinib |
DP-5164; DCC-2701; DCC-22701; T-678746713 |
Phase 1 Clinical |
Deciphera |
Solid tumours; Neoplasms |
Details
|
MSB-0254 |
MSB-0254 |
Phase 1 Clinical |
Mabspace Biosciences Co Ltd |
Solid tumours |
Details
|
AXT-107 |
AXT-107 |
Phase 2 Clinical |
AsclepiX Therapeutics Inc |
Diabetic macular oedema; Macular Degeneration |
Details
|
VEGFR2 peptide vaccine (Tokyo University) |
|
Phase 1 Clinical |
University Of Tokyo |
Pancreatic Neoplasms |
Details
|
AVI-3207 |
AVI-3207 |
Phase 1 Clinical |
Avixgen |
Macular Degeneration |
Details
|
Sitravatinib |
MG-516; MG-91516; MGCD-516; IND-155305 |
Phase 3 Clinical |
Mirati Therapeutics |
Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular |
Details
|
FNX-006 |
FNX-006 |
Phase 1 Clinical |
Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd |
Triple Negative Breast Neoplasms; Melanoma |
Details
|
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) |
NP-01 |
Phase 1 Clinical |
Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd |
Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms |
Details
|
BR-55 |
BR-55 |
Phase 2 Clinical |
Sonus Pharmaceuticals |
Ovarian Neoplasms; Prostatic Neoplasms; Diagnostic agents |
Details
|
Ramucirumab biosimilar (Henlius) |
HLX-12 |
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Pamufetinib |
TAS-115 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) |
|
Phase 1 Clinical |
Sichuan Kelun Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Telatinib |
EOC-315; BAY-57-9352 |
Phase 2 Clinical |
Bayer Ag |
Solid tumours; Stomach Neoplasms |
Details
|
Hydroxychloroquine/Sorafenib |
|
Phase 1 Clinical |
Vg Life Sciences |
Ovarian Neoplasms |
Details
|
QBH-196 |
QBH-196 |
Phase 1 Clinical |
Shenyang Pharmaceutical University |
Solid tumours; Stomach Neoplasms |
Details
|
Tafetinib Malate |
SIM-0702; SIM-1005; SIM-010603 |
Phase 1 Clinical |
Jiangsu Xiansheng Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
KC1036 |
KC1036; KC-1036 |
Phase 1 Clinical |
Beijing Konruns Pharmaceutical Co Ltd |
Hematologic Neoplasms; Solid tumours |
Details
|
Ningetinib Tosylate |
CT-053; CT-053-PTSA |
Phase 2 Clinical |
Hec Pharm Co Ltd |
Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
LM-061 |
LM-061 |
Phase 2 Clinical |
Shanghai Lixin Pharmaceutical Research and Development Co Ltd |
Congenital Hyperinsulinism; Solid tumours |
Details
|
KDR2-2 |
|
Phase 2 Clinical |
Guangzhou Huiborui Biomedical Technology Co Ltd |
Glaucoma, Neovascular; Corneal Neovascularization |
Details
|
Brivanib Alaninate |
ZL-2301; BMS-540215; BMS-582664 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Liver Neoplasms; Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Sarcoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|
Pulocimab |
AK-109 |
Phase 2 Clinical |
Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma |
Details
|
Chiauranib |
CS-2164 |
Phase 3 Clinical |
Shenzhen Chipscreen Biosciences Co Ltd |
Solid tumours; Ovarian Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular |
Details
|
Famitinib Malate |
SHR-1020 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Fallopian Tube Neoplasms; Urogenital Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Ovarian Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Nasopharyngeal Carcinoma; Idiopathic Pulmonary Fibrosis; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours |
Details
|
JY-025 |
JY-025 |
Phase 3 Clinical |
Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
MG-D-1609 |
MG-D-1609 |
Phase 2 Clinical |
Metagone Biotech |
Solid tumours |
Details
|
Sorafenib/MG-005 |
MGD-1509; MG-D-1509 |
Phase 1 Clinical |
Metagone Biotech, Tri-Service General Hospital |
Solid tumours |
Details
|
Gentuximab |
|
Phase 1 Clinical |
Genescience Pharmaceuticals Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|